このエントリーをはてなブックマークに追加
ID 56992
FullText URL
Author
Inamoto, Yoshihiro National Cancer Center Hospital
Matsuda, Tomohiro National Cancer Center Hospital
Tabuchi, Ken Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
Kurosawa, Saiko National Cancer Center Hospital
Nakasone, Hideki Saitama Medical Center, Jichi Medical University
Nishimori, Hisakazu Okayama University Hospital
Yamasaki, Satoshi National Hospital Organization Kyushu Medical Center
Doki, Noriko Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
Iwato, Koji Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Mori, Takehiko Keio University School of Medicine
Takahashi, Satoshi The Institute of Medical Science, The University of Tokyo
Yabe, Hiromasa Tokai University Hospital,
Kohno, Akio JA Aichi Konan Kosei Hospital
Nakamae, Hirohisa Osaka City University
Sakura, Toru Saiseikai Maebashi Hospital
Hashimoto, Hisako Kobe City Medical Center General Hospital
Sugita, Junichi Hokkaido University Hospital
Ago, Hiroatsu Shimane Prefectural Central Hospital
Fukuda, Takahiro National Cancer Center Hospital
Ichinohe, Tatsuo Research Institute for Radiation Biology and Medicine, Hiroshima University
Atsuta, Yoshiko Japanese Data Center for Hematopoietic Cell Transplantation
Yamashita, Takuya St. Luke's International Hospital
Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group
Abstract
To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (P < .001). The overall survival probability was 60% at 3 years after diagnosis of subsequent solid cancer and differed according to cancer type. Development of most solid cancers was associated with an increased risk of subsequent mortality after HCT. Subsequent solid cancers accounted for 76% of causes of death. Overall survival probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population than in the general population for colon, bone/soft tissue, and central nervous system cancers and did not differ statistically for other cancers. In conclusion, most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages. Subsequent solid cancers showed similar or worse survival compared with primary cancers. Biological and genetic differences between primary and subsequent solid cancers remain to be determined.
Published Date
2018-08
Publication Title
Blood Advances
Volume
volume2
Issue
issue15
Publisher
American Society of Hematology
Start Page
1901
End Page
1903
ISSN
2473-9529
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
File Version
publisher
PubMed ID
DOI
Related Url
isVersionOf https://doi.org/10.1182/bloodadvances.2018020966